Reaction
Primary Biliary Cholangitis reporting signals
As of the last recalculation, Primary Biliary Cholangitis appears in 456 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is URSOSIOL (PRR 83.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ursosiol | 33 | 83.5 | 83.6 |
| Ursodiol | 34 | 76.9 | 77.0 |
| Remdesivir | 7 | 24.3 | 24.3 |
| Ado-Trastuzumab Emtansine | 4 | 21.8 | 21.8 |
| Selexipag | 12 | 21.7 | 21.8 |
| Rifaximin | 8 | 17.7 | 17.7 |
| Bosutinib | 3 | 15.3 | 15.3 |
| Encorafenib | 3 | 13.9 | 13.9 |